147 related articles for article (PubMed ID: 16822929)
1. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.
Sarnataro D; Pisanti S; Santoro A; Gazzerro P; Malfitano AM; Laezza C; Bifulco M
Mol Pharmacol; 2006 Oct; 70(4):1298-306. PubMed ID: 16822929
[TBL] [Abstract][Full Text] [Related]
2. The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.
Malfitano AM; Laezza C; Galgani M; Matarese G; D'Alessandro A; Gazzerro P; Bifulco M
Pharmacol Res; 2012 Mar; 65(3):365-71. PubMed ID: 22123497
[TBL] [Abstract][Full Text] [Related]
3. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells.
Malfitano AM; Laezza C; Pisanti S; Gazzerro P; Bifulco M
Br J Pharmacol; 2008 Mar; 153(5):1003-10. PubMed ID: 18157162
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.
Ciaglia E; Torelli G; Pisanti S; Picardi P; D'Alessandro A; Laezza C; Malfitano AM; Fiore D; Pagano Zottola AC; Proto MC; Catapano G; Gazzerro P; Bifulco M
Oncotarget; 2015 Jun; 6(17):15464-81. PubMed ID: 26008966
[TBL] [Abstract][Full Text] [Related]
5. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.
Gary-Bobo M; Elachouri G; Scatton B; Le Fur G; Oury-Donat F; Bensaid M
Mol Pharmacol; 2006 Feb; 69(2):471-8. PubMed ID: 16282221
[TBL] [Abstract][Full Text] [Related]
6. Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells.
Dai E; Zhang J; Zhang D; Yang L; Wang Y; Jiang X; Ye L; Li X; Liu H; Ma J; Jiang H
Hepatogastroenterology; 2014 Oct; 61(135):2052-61. PubMed ID: 25713910
[TBL] [Abstract][Full Text] [Related]
7. Anandamide inhibits adhesion and migration of breast cancer cells.
Grimaldi C; Pisanti S; Laezza C; Malfitano AM; Santoro A; Vitale M; Caruso MG; Notarnicola M; Iacuzzo I; Portella G; Di Marzo V; Bifulco M
Exp Cell Res; 2006 Feb; 312(4):363-73. PubMed ID: 16343481
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.
Gazzerro P; Malfitano AM; Proto MC; Santoro A; Pisanti S; Caruso MG; Notarnicola M; Messa C; Laezza C; Misso G; Caraglia M; Bifulco M
Oncol Rep; 2010 Jan; 23(1):171-5. PubMed ID: 19956878
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
[TBL] [Abstract][Full Text] [Related]
10. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
[TBL] [Abstract][Full Text] [Related]
11. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.
Nam DH; Lee MH; Kim JE; Song HK; Kang YS; Lee JE; Kim HW; Cha JJ; Hyun YY; Kim SH; Han SY; Han KH; Han JY; Cha DR
Endocrinology; 2012 Mar; 153(3):1387-96. PubMed ID: 22234468
[TBL] [Abstract][Full Text] [Related]
12. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
[TBL] [Abstract][Full Text] [Related]
13. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase.
Esposito I; Proto MC; Gazzerro P; Laezza C; Miele C; Alberobello AT; D'Esposito V; Beguinot F; Formisano P; Bifulco M
Mol Pharmacol; 2008 Dec; 74(6):1678-86. PubMed ID: 18801918
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
15. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.
Santoro A; Pisanti S; Grimaldi C; Izzo AA; Borrelli F; Proto MC; Malfitano AM; Gazzerro P; Laezza C; Bifulco M
Int J Cancer; 2009 Sep; 125(5):996-1003. PubMed ID: 19479993
[TBL] [Abstract][Full Text] [Related]
16. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
[TBL] [Abstract][Full Text] [Related]
17. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells.
Sarnataro D; Grimaldi C; Pisanti S; Gazzerro P; Laezza C; Zurzolo C; Bifulco M
FEBS Lett; 2005 Nov; 579(28):6343-9. PubMed ID: 16263116
[TBL] [Abstract][Full Text] [Related]
18. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.
Croci T; Landi M; Galzin AM; Marini P
Br J Pharmacol; 2003 Sep; 140(1):115-22. PubMed ID: 12967941
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.
Tedesco L; Valerio A; Cervino C; Cardile A; Pagano C; Vettor R; Pasquali R; Carruba MO; Marsicano G; Lutz B; Pagotto U; Nisoli E
Diabetes; 2008 Aug; 57(8):2028-36. PubMed ID: 18477809
[TBL] [Abstract][Full Text] [Related]
20. Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates.
Foltin RW; Haney M
Pharmacol Biochem Behav; 2007 Apr; 86(4):766-73. PubMed ID: 17445873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
